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The airway epithelium participates in chronic airway inflammation by expressing adhesion
molecules that mediate the transmigration of neutrophils into the inflamed airways. We
hypothesize that, in patients with bronchiectasis, cytokines in their bronchial secretions
enhance the expression of intercellular cell adhesion molecule (ICAM-1) in the bronchial
epithelium and thus contribute to sustained recruitment of neutrophils into the inflamed
airways. In the present study, we investigated the effect of bronchial secretions on the
regulation of ICAM-1 in bronchial epithelial cells, and its modulation by pharmacologic
agents. The expression of ICAM-1 mRNA and protein in human bronchial epithelial cells
upon exposure to sputum sol from subjects with bronchiectasis were evaluated by reverse
transcription-polymerase chain reaction (RT-PCR) and ELISA, respectively. Modulating
effects of dexamethasone, ibuprofen, MK-663 or triptolide on ICAM-1 regulation were
investigated in vitro. We demonstrated that changes in ICAM-1 expression correlated with
levels of TNF-a in the sputum sol, and treatment of sol samples with TNF-a antibodies
attenuated both the increase in ICAM-1 mRNA and protein. The role of TNF-a was further
demonstrated when TNF-a elicited dose dependent increase in ICAM-1 expression. The
sputum effect could also be suppressed dose-dependently by pre-incubation of bronchial
epithelial cells with dexamethasone, ibuprofen, MK-663 or triptolide. Evidence is thus
provided for the upregulation of bronchial epithelial ICAM-1 expression by airwayElsevier Ltd. All rights reserved.
helial cell growth medium; ELISA, enzyme-linked immunosorbent assay; ICAM-1, intercellular cell
b; IL-6, interleukin 6; IL-8, interleukin 8; NHBE, normal human bronchial epithelial cells; TNF-a, tumor
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S.C.H. Chan et al.288secretions in bronchiectasis and a specific role for TNF-a in the secretions. The success of
drug attenuation of this upregulation provides insight into possible therapeutic paradigms
in the management of the disease.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Bronchiectasis is characterized by irreversibly dilated
bronchi that are chronically inflamed and often colonized
by bacteria. Intense and persistent neutrophil recruitment
to the airways and the release of neutrophil elastase
are hallmarks in the pathogenesis of bronchiectasis.1–5
Recruitment of neutrophils to the airways depends on a
stepwise process which allows neutrophils to transmigrate
across the vascular endothelium, airway epithelium and
eventually into the airway lumen. Activation and adhesion
of neutrophils onto bronchial epithelial cells is regulated by
a cytokine cascade and specific adhesion molecules.6–8
Among various adhesion molecules, intercellular cell adhe-
sion molecule-1 (ICAM-1), a transmembrane glycoprotein of
505 amino acids, mediates the interaction between the
neutrophils and bronchial epithelial cells.9,10 ICAM-1 is
constitutively expressed on endothelium, epithelium and
neutrophils, and its upregulation is triggered by a number of
inflammatory mediators, including interferon-g, interleukin-
1b (IL-1b) and tumor necrosis factor-a (TNF-a).11,12 Upregu-
lated expression of ICAM-1 has been demonstrated in
patients with asthma, COPD and bronchiectasis.7,13,14
Increased expression of alveolar epithelial ICAM-1 was
reported to enhance adherence of neutrophils and macro-
phages in vivo and in vitro,15 suggesting a biological function
of ICAM-1 in the perpetuation of bronchial injury. This study
was designed to determine the effects of secretions from
inflamed airways on ICAM-1 expression in bronchial epithe-
lium, specifically the role of TNF-a. The study further
explored the use of pharmacologic agents, including anti-
body against TNF-a, glucocorticoid, cox-1 and cox-2 in-
hibitors, and triptolide, a Chinese herbal extract, in
modulating the sputum effect.Methods
Reagents and antibodies
Dexamethasone, ibuprofen and nimodipine were products of
Sigma (St. Louis, MO, USA) and MK-663 (COX-2 inhibitor)
was obtained from the Merck Research Laboratory.
Triptolide was kindly provided by Professor DQ Yu (Chinese
Academy of Medical Sciences, Beijing, China). Dexametha-
sone and ibuprofen were prepared in methanol, MK-663
was prepared in distilled water and triptolide was pre-
pared in ethanol/acetone (v/v, 1:1), nimodipine was first
dissolved in DMSO and then diluted in cell culture medium to
the working concentration. Recombinant human tumor
necrosis factor-a (rh TNF-a), anti-human TNF-a and anti-
human IL-1b were obtained from PeproTech EC Ltd.
(London, UK).Subjects and sputum samples processing
Patients with bronchiectasis were recruited from the
Bronchiectasis Clinic, The University of Hong Kong, Queen
Mary Hospital. Inclusion criteria were: bronchiectasis docu-
mented on high resolution computerized tomography (HRCT)
of chest; idiopathic etiology of bronchiectasis; chronic
sputum production with daily sputum 410ml; absence of
asthma (according to American Thoracic Society guide-
lines)16 and other major pulmonary diagnoses; and a steady
state as defined by absence of change of symptoms noted by
the patient over the past 3 weeks. Exclusion criteria were:
bronchiectasis with defined etiology (e.g. post-tuberculous,
primary ciliary dyskinesia, common variable immunodefi-
ciency); maintenance use of oral or nebulized antibiotics;
use of antibiotics within the previous 3 weeks. A sweat test
has not been performed to exclude cystic fibrosis because of
the known rarity of cystic fibrosis among Chinese and the
lack of suggestion of multi-system disease in any of the
patients. Lung function testing was done using SensorMedics
2200 (SensorMedics, Yorba Linda, CA) lung function system.
Sputum samples were collected over a maximum of 4 h in
sterile pots. Patients taking inhaled bronchodilators or
inhaled corticosteroids have been advised to omit these
drugs for at least 12 h before sputa were collected.
Healthy subjects who were asymptomatic of respiratory
diseases and have not been receiving regular medications
were recruited randomly from laboratory personnel. Sputum
induction in healthy volunteers was performed using a
method as described by Keatings et al.17 Induced sputum
from healthy subjects were used as control for studying the
effect of sputum sol from bronchiectasis subjects on ICAM-1
expression in bronchial epithelial cells. Expectorated
sputum from both patients and control subjects were
examined under light microscopy and presence of X10
buccal squamous epithelial cells per field ( 100 magnifica-
tion), as average of 10 fields, being considered to indicate a
salivary origin, and samples were excluded from further
processing. Sputum samples from patients were also sent for
microbiological examination using standard techniques. The
bulk of the collected sputum samples were immediately
centrifuged at 50,000g for 1.5 h (4 1C); the supernatant sol
phase of each sample was collected, aliquoted and stored at
80 1C until use.
The study has been approved by The University of Hong
Kong Ethics Committee; patients and healthy volunteers
gave written informed consent before sputum collection.
Primary culture of human bronchial epithelial cells
Normal human bronchial epithelial cells (NHBE) (Clonetics,
San Diego, CA, USA) were cultured in bronchial epithelial
cell growth medium (BEGM) (Clonetics) containing bovine
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human epidermal growth factor (0.5 ng/ml), epinephrine
(0.5 mg/ml), transferrin (10 mg/ml), insulin (5 mg/ml), reti-
noic acid (1 ng/ml), triiodothyronine (6.51 ng/ml), gentami-
cin (50 mg/ml) and bovine serum albumin (500 mg/ml) at
37 1C and 5% CO2. Cell viability was checked with trypan blue
exclusion test to ensure no significant difference between
various experiments and to ascertain that cells were viable
after incubation with the high concentrations of drugs used
in the study.
Assay of TNF-a level in sputum sol
The protein level of TNF-a in the sputum sol phase was
measured with the use of a quantitative sandwich enzyme-
linked immunosorbent assay (ELISA) kit (PeproTech, London,
UK) as described by Shum et al.8 Samples (100 ml) of diluted
sputum sol were dispensed into wells of microtiter plates
which had been coated with monoclonal anti-human TNF-a.
After incubation for 3 h at room temperature, the wells
were first washed with phosphate-buffered saline (PBS) and
then incubated with an enzyme-linked polyclonal rabbit
antibody directed against TNF-a for another 45min at room
temperature. After further rinses with PBS to remove the
unbound antibodies, substrate solution (40ml) was added to
each well and incubated for 20min at 37 1C. The reaction
was terminated with the addition of a ‘‘stop’’ solution (0.5M
sulfuric acid, 100 ml). Assays were performed in duplicate.
Absorbance was measured at 492 nm in an ELISA reader.
Values were determined relative to a standard curve.
Quantification of NHBE expression of ICAM-1 protein
The level of ICAM-1 expression was determined by ELISA as
described previously.18 NHBE cells (1 105 cells per well)
were washed twice with PBS and fixed at room temperature
with 4% paraformaldehyde for 10min. After washing with
PBS, they were blocked with 1% BSA in Tris-buffered saline
containing 0.05% Tween 20 for 15min. The cells were then
incubated sequentially with mouse anti-human ICAM-1
antibody (primary antibody, diluted 1:100; Chemicon, CA,
USA) for 1 h and horseradish peroxidase-labeled anti-mouse
antibody (secondary antibody, 1:1000, serotec, oxford, UK)
for 30min. OPD substrate (0.4mg/ml in phosphate-citrate
buffer, pH 5.0; 24.3mM citric acid, 51.4mM Na2HPO4 
12H2O, 12% H2O2, v/v) was then applied to the cells for
30min and sulfuric acid (3M) was added to stop the
reaction. Each assay was performed in triplicate. Absor-
bance was measured at 450 nm in an ELISA reader and
corrected for background by subtracting the absorbance of
controls in which the primary antibody had been omitted.
Treatment of NHBE cells with sputum sol, anti-TNF-
a, anti-IL-1b or rh-TNF-a
Sputum sol samples (100 ml) were incubated with NHBE cell
cultures at 37 1C and 5% CO2 for 8 h. To prevent cell
detachment by the action of sputum elastase and metallo-
proteinases, the culture medium was supplemented with
eglin C (0.05M; a specific inhibitor of neutrophil elastase,
Sigma), and EDTA (0.05M). Treatments were performed intriplicate for each sputum sol sample. Parallel incubations of
NHBE cells with two induced control sputum samples were
performed. The cells were then assessed for ICAM-1 mRNA
expression by semi-quantitative reverse transcription-poly-
merase chain reaction (RT-PCR) and for ICAM-1 protein
by ELISA. To neutralize the effects of sputum sol TNF-a and
IL-1b on the NHBE cells, sputum sol samples were pre-
incubated (4 1C) with anti-TNF-a or anti-IL-1b for 1 h prior to
the incubation with NHBE cells for 8 h. Alternatively, rh-TNF-
a was added to NHBE cell cultures at concentrations
of 50–1000 pg/ml and incubated for 8 h. ICAM-1 mRNA
and protein expression was assessed by semi-quantitative
RT-PCR and ELISA, respectively.
Treatment of NHBE cells with anti-inflammatory
drugs
To evaluate the potential effect of various anti-inflamma-
tory drugs on ICAM-1 mRNA expression, the NHBE cells were
first treated with dexamethasone, ibuprofen, MK-663,
triptolide or nimodipine for 1 h prior to the stimulation with
sputum sol samples for 8 h. The drug concentrations were
chosen on the basis of data from previously published
studies19–22 or from the supplier (Merck Research Laboratory
for MK-663; Sigma for nimodipine). Incubations of NHBE cells
was performed with two control sputum simultaneously.
ICAM-1 mRNA and protein expression was assessed by semi-
quantitative RT-PCR and ELISA, respectively.
Assay with actinomycin D and cycloheximide
NHBE cells were first treated with either 5mg/ml of
actinomycin D (Sigma) or 50 mg/ml cycloheximide (Sigma)
for 1 h prior to the stimulation with sputum sol samples for
8 h. ICAM-1 mRNA expression was assayed semi-quantita-
tively with RT-PCR and the level of ICAM-1 protein
expression was determined by ELISA as described.
RT-PCR analysis of ICAM-1 mRNA expression
Total RNA was extracted from the cells by the RNeasys Mini
kit (Qiagen, Valencia, CA, USA). The extracted RNA samples
were quantified by measurement of absorbance at 260 nm
using GeneQuantTM (Amersham Biosciences, Piscataway, NJ,
USA). RNA (2 mg) from each sample was reversed transcribed
into cDNA with random oligo (dT) primers and SuperScriptTM
II reverse transcriptase (Invitrogen, Carlsbad, CA, USA).
Equal amounts of the cDNA were amplified with PCR in a
final volume of 20 ml. The primers for amplifying ICAM-1
cDNA were: forward 50-TATGGCAACGACTCCTTCT-30 and
reverse 50-CATTCAGCGTCACCTTGG-30. The primers for am-
plifying glyceraldehyde phosphate dehydrogenase (GAPDH)
cDNA were: forward 50-CCTTCATTGACCTCAACTACATGGT-30
and reverse 50-TCGTTGTCATACCAGGAAATGAGCT-30. The PCR
reagents and Taq polymerase were purchased from (Invitro-
gen). Amplification was started with denaturation at 95 1C
(12min) followed by 30 cycles for ICAM-1 and 25 cycles for
GAPDH. Each cycle consisted of 2min at 95 1C, 30 s at 55 1C
(for GAPDH, 1min at 60 1C) and 90 s at 72 1C. The final
extension was 10min at 72 1C. After amplification, PCR
products (5 ml each) were separated by electrophoresis in a
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results were visualized under ultraviolet light. The PCR
signals were quantified using the Image J quantification
software (National Institute of Health, USA). For each
sample, ICAM-1 signal was normalized against that of the
house-keeping gene, GAPDH and expressed as signal ratios of
ICAM-1/GAPDH.Statistical analysis
Data were expressed as mean7S.D. The INSTAT and PRISM
statistical software packages (GraphPad Inc., San Diego, CA)
were used for the statistical analyses. Data were analyzed
by one-way analysis of variance (ANOVA) with a Bonferroni’s
post hoc test. Correlation between ICAM-1 protein expres-
sion in NHBC cells and sputum TNF-a level in the culture
medium was determined with Spearman’s rank correlation
test. A P-value of o0.05 was considered statistically
significant.Results
Clinical characteristics
This study recruited 12 subjects with idiopathic bronchiec-
tasis proven by HRCTscan of thorax and 6 healthy volunteers
as controls. Their demographic and clinical features are
shown in Table 1.Table 1 Characteristics of study subjects.
Patients with
bronchiectasis
Healthy
controls
Sex (M:F) 6:6 4:2
Age (year) 48717 2874
Sputum microbiology profile
Pseudomonas
aeruginosa
3 N/A
Hemophilus
influenzae
1 N/A
Commensals 8 N/A
Lung function test results
FEV1 (L)
 1.270.7 Not measured
FVC (L) 2.270.7 Not measured
Smoking habit
Non-smoker 12 (100%) 6 (100%)
HRCT thorax
No. of lobes
affectedy
3 (2–5) N/A
N/A: not applicable.
Values are expressed as mean7S.D.
yValues are expressed as median (range).Sputum samples of patients with bronchiectasis
stimulate NHBE expression of ICAM-1
The level of ICAM-1 mRNA in the primary cultures of NHBE
cells was increased with exposure to sputum sol samples of
12 patients with bronchiectasis. Test samples of sputum sol
elicited a 1.7-fold increase in ICAM-1 mRNA expression when
compared with the six induced sputum controls (0.7370.10
vs. 0.4270.03, ICAM-1/GAPDH ratio) (Figure 1a). Similarly,
exposure of cultures of NHBE cells to sputum sol samples
elicited a 1.8-fold increase in ICAM-1 protein levels when
compared with the six induced sputum controls (0.8570.10
vs. 0.4770.03) in terms of absorbance at 450 nm)
(Figure 1b).
TNF-a is a key sputum cytokine that stimulates
NHBE expression of ICAM-1
NHBE expression of ICAM-1 protein was found to correlate
with the level of TNF-a as presented by sputum sol samples
in the NHBE culture medium (r ¼ 0.9441, Po0.001, Figure 2).
Pre-incubation of sputum sol samples with commensurate
level of neutralizing antibody against TNF-a resulted in
significant reduction of both ICAM-1 mRNA and protein
expression in contrast to the insignificant reduction of ICAM-
expression in anti-IL-1b-treated samples (Figure 3a and b).
Treatment of NHBE cells with rh-TNF-a resulted in dose-
dependent significant increase in both ICAM-1 mRNA and
protein expression (Figure 4a and b).
Effect of actinomycin D and cycloheximide on
sputum sol induced ICAM-1 expression
Pretreatment of the NHBE cells with a RNA polymerase
inhibitor, actinomycin D, resulted in a decrease in ICAM-1
mRNA level while cycloheximide, a protein synthesis
inhibitor, did not inhibit upregulation of ICAM-1 at mRNA
level (Figure 5a). On the other hand, both actinomycin D
and cycloheximide inhibited ICAM-1 protein expression
(Figure 5b).
Effect of dexamethasone, ibuprofen, MK-663 and
triptolide on ICAM-1 expression
Pretreatment of NHBE cells with 0.2mM dexamethasone
decreased ICAM-1 expression but this was not statistically
significant (P ¼ 0.065). However, higher concentrations of
dexamthasone (2–20 mM) resulted in dose-dependent sig-
nificant decrease in ICAM-1 mRNA and protein expression
when compared with the sputum sol-stimulated NHBE cells
(Figure 6a and b).
Similarly, pretreatment of the NHBE cells with MK-663
(2–200 mM) or iburopfen (2–200 mM) resulted in dose-depen-
dent down-regulation of ICAM-1 expression when compared
with the sputum sol-stimulated NHBE cells (Figure 6a and b).
On the other hand, triptolide was more potent than the
other anti-inflammatory agents tested in our study. Pre-
treatment of the NHBE cells with much lower concentrations
(0.02–2 mM) of triptolide dose-dependently down-regulated
ICAM expression to level achieved with the other drugs
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Figure 1 The effect of sputum sol samples from patients with bronchiectasis on NHBE expression of ICAM-1. (a) Total RNAs were
extracted from the NHBE cells after incubation with sputum sol samples of patients with bronchiectasis or induced sputum of healthy
volunteers and analyzed for ICAM-1 mRNA expression by RT-PCR. The top panel shows gel bands due to PCR amplification products of
ICAM-1 (238 bp) and GAPDH (844 bp) transcripts. ICAM-1 mRNA was assessed by integration of pixel density of the band and expressed
as a ratio to that of GAPDH mRNA. (b) NHBE expression of ICAM-1 protein as a result of incubation with sputum sol samples of patients
with bronchiectasis or induced sputum of healthy volunteers. ICAM-1 protein was determined with ELISA and expressed in terms of
absorbance at 450 nm, net that of background. The data, shown as mean7S.D., were derived from 12 sputum samples from patients
with bronchiectasis and 6 induced sputum samples from healthy volunteers, each tested in triplicate. ***Po0.001.
Upregulation of ICAM-1 expression in bronchiectasis 291(Figure 6a and b). Nimodipine, a calcium channel blocker,
serve as a negative control in our experiment. Pretreatment
of NHBE cells with nimodipine showed no significant effect
on ICAM-1 expression in sputum sol-stimulated NHBE cells
(Figure 6a and b).
The inhibitory effect on ICAM-1 expression was not
related to toxicity of these drugs since epithelial cells
remained 98% viable as determined by the Trypan blue dye
exclusion test at the end of the culture periods. In addition,pre-incubation of NHBE cells with drug vehicles (methanol,
ethanol, acetone and DMSO) showed no significant effect on
ICAM-1 expression (results not shown).Discussion
The major findings in this study were that bronchial
secretions of patients with idiopathic bronchiectasis were
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Figure 2 Correlation between NHBE expression of ICAM-1 protein and TNF-a level as presented by bronchiectasis patient sputum sol
samples in the culture medium. Sputum sol samples (100 ml each) were diluted 1-in-10 (v/v) in NHBE culture media during the 8-h
incubation. Accordingly, the concentration of TNF-a measured by ELISA in 100 ml of undiluted sputum was pro-rated to that in the
medium for the plot against NHBE expression of ICAM-1. Spearman’s correlation coefficient (r) and its significance (P) are indicated.
S.C.H. Chan et al.292active in upregulating expression of ICAM-1 mRNA and ICAM-1
protein by human bronchial epithelial cells in vitro, and that
TNF-a in the sputum sol samples was responsible for this
effect. Apart from the neutralizing effect of anti-TNF-a
antibody, pharmacologic agents including dexamethasone,
ibuprofen, MK-663 and triptolide were shown to counteract
the sputum effect on ICAM-1 upregulation.
Neutrophil recruitment represents an important event of
host response to injury, although the end result may not
always be favorable to host tissues. The pathogenesis of
bronchiectasis has been shown to involve persistent recruit-
ment of neutrophils from the circulation into the bronchial
lumen with subsequent release of enzymes leading to airway
damage.1–5
ICAM-1, a member of the immunoglobulin superfamily, is
one of the important components that play critical roles in
neutrophil recruitment and adhesion towards the damaged
tissues.23 ICAM-1 upregulation can be triggered by extra-
vascular bacterial products and pro-inflammatory mediators
derived from the epithelium.24,25 Both in vivo and in vitro
studies have demonstrated that bacterial lipopolysaccharide
and pro-inflammatory cytokines including IL-1b, TNF-a and
IFN-g upregulated the expression of ICAM-1 in airway
epithelial cells.9,11,12 High levels of IL-1b, TNF-a, and IL-8
have been consistently found in the expectorated bronchial
secretions of patients with bronchiectasis.2,26 TNF-a has
been reported to play important roles in neutrophil-
mediated degradation of lung matrix components in
bronchiectasis8 and induction of the expression of IL-827
and IL-6.28 In this study, we demonstrated that TNF-a in
bronchial secretions of patients with bronchiectasis is a
major mediator in the upregulation of ICAM-1 expression in
human bronchial epithelial cells.
There has been great interest in the use of various anti-
inflammatory drugs to overcome chronic inflammation
cascade in disease. The key roles of TNF-a in initiatinginflammatory and maintaining cellular immune responses
have led to the development of new therapies. Anti-TNF-a
agents including infliximab (Remicades), etanercept
(Enbrels) and adalimumab (Humiras) have demonstrated
efficacy in the treatment of rheumatoid arthritis29 and
inflammatory bowel disease.30 However, as non-selective
blockade of TNF may well result in increased infections, and
there has been reports of increased risk of reactivation of
tuberculosis in subjects treated with anti-TNF-a.31 In
particular, bronchiectasis is a condition with persistent
microbial colonization, the risk of worsening the infective
component cannot be over-emphasized.32 The in vitro
antagonistic effect of anti-TNF antibody on NHBE upregula-
tion of ICAM-1 confirmed the role of TNF-a as an inflamma-
tory mediator in bronchiectasis, although the use of anti-
TNF-a agent may not be beneficial to the patients of
bronchiectais.
Dexamethasone is a potent steroid widely used in
treatments of inflammatory conditions. Oral prednisolone
has been reported to improve clinical parameters in children
with cystic fibrosis,33 but side-effects of long-term use
prohibit its clinical utility. Inhaled steroids have been shown
to down-regulate inflammatory mediators in bronchiecta-
sis.26 However, a randomized trial of inhaled fluticasone only
showed a decrease in sputum volume but no change in FEV1
or frequency of exacerbation.34 Previous studies have shown
that 0.1mM dexamethasone can effectively down-regulate
TNF-a and rhinovirus-induced ICAM-1 expression in both
human nasal epithelial cells35 and A549 type II pulmonary
cells.36 In our study, 0.2mM dexamethasone did not
significantly inhibit ICAM-1 expression, while higher con-
centrations (2 and 20 mM) showed definite inhibitory effects.
This suggests that there may be other factors in the sputum
sol that can counteract the action of dexamethasone on
ICAM-1 expression. The in vitro findings support the advant-
ageous edge of using inhalational route of administration
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Figure 3 Anti-TNF-a counteracted sputum sol stimulation of NHBE expression of ICAM-1. Sputum sol samples had been pre-
incubated with either anti-TNF-a (5 ng/ml) or anti-IL 1b (5 ng/ml) 1 h prior to incubation with NHBE cells. (a) ICAM-1 mRNA data are
expressed in terms of ratios (ICAM-1:GAPDH) of pixel densities due to the respective PCR products, and plotted as % relative to that
of control incubations. (b) ICAM-1 protein levels are expressed in terms of absorbance at 450 nm, net that of background. The net
absorbance was plotted as % of that due to control incubations. The data, shown as mean7S.D., were derived from 12 sputum sol
samples, each tested in triplicate.
Upregulation of ICAM-1 expression in bronchiectasis 293in vivo as this can achieve much higher concentrations in the
airway epithelium, giving a more acceptable effect–side
effect profile compared to systemic steroids.
Clinical studies have demonstrated the use of NSAID and
selective COX-2 inhibitors to attenuate the inflammatoryresponse. Inhalation of indomethacin was found to reduce
the sputum volume in patients with chronic bronchitis and
bronchiectasis.37 Systemic administration of indomethacin
however resulted in no improvements in sputum albumin,
elastase and myeloperoxidase levels.38 Ibuprofen was
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Figure 4 NHBE upregulation of ICAM-1 expression as a result of stimulation with recombinant TNF-a. Dose-dependent increase of
ICAM-1 expression in NHBE cells as elicited by recombinant TNF-a. NHBE cells were treated with recombinant TNF-alpha (50, 200 and
1000 pg/ml). (a) ICAM-1 mRNA data are expressed in terms of ratios (ICAM-1:GAPDH) of pixel densities due to the respective PCR
products. The ratios were plotted as %, relative to that of null treatment. (b) ICAM-1 protein levels are expressed in terms of
absorbance at 450 nm, net that of background. The net absorbances were plotted as % of that due to null treatment. The data, shown
as mean7S.D., were derived from five independent experiments, each performed in triplicate. Po0.01, Po0.001.
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Figure 5 The effect of ACTD and CHX on ICAM-1 mRNA and protein expression in sputum sol stimulated NHBE cells. Lack of increase
in ICAM-1 mRNA and protein level when sputum sol-stimulated NHBE cells was treated with actinomycin D and cycloheximide,
respectively. (a) ICAM-1 mRNA data are expressed in terms of ratios (ICAM-1:GAPDH) of pixel densities due to the respective PCR
products. The data are plotted as %, relative to that of control incubations. (b) ICAM-1 protein levels are expressed in terms of
absorbance at 450 nm, net that of background. The net absorbances were plotted as % of that due to control incubations. The data,
shown as mean7S.D., were derived from five independent experiments, each tested in triplicate. Po0.001 when compared with
NHBE cultures that were stimulated with sputum sol.
Upregulation of ICAM-1 expression in bronchiectasis 295reported to improve clinical manifestations of bronchiecta-
sis in cystic fibrosis,33 while in vitro studies showed that
ibuprofen and cyclooxygenase-2 inhibitors down-regulated
cytokine-induced ICAM-1 expression.37,39 Our findings sup-
port that these agents may be able to interrupt the
inflammatory cycle in bronchiectasis.
The use of triptolide in the treatment of inflammatory
diseases has largely been based on extracts of the Chinese
herb, Tripterygium wilfordii. Although oral doses of several
hundred milligrams of extract per day appeared to be safe
and beneficial to patients with rheumatoid arthritis, it isunclear how these compare with nanomolar triptolide
delivered to environments of cells in culture. It is however
noteworthy that a 20–140 nM range was used effectively to
interfere with expression of pro-inflammatory cytokines,
proMMPs and to upregulate TIMPs in IL-1-treated synovial
fibroblasts.40 Incidentally, this approximated the IC50 of
50–140 nM for down-regulation of pro-inflammatory cyto-
kines as stimulated by phorbol ester, TNF-a or IL-1b
treatment of human bronchial epithelial cells in culture.22
Thus, anti-inflammatory efficacy may be comparable at the
cell level but clinical dosing may well differ on account of
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Figure 6 Inhibitory effects of anti-inflammatory drugs on sputum sol stimulation of NHBE expression of ICAM-1. Dexamethasone
(0.20, 2 and 20 mM), ibuprofen (2, 20 and 200 mM), MK-663 (2, 20 and 200 mM) and triptolide (0.02, 0.20 and 2 mM) showed dose-
dependent inhibition of the sputum effect on ICAM-1 expression. Nimodipine (2, 20 and 200 mM), a calcium channel blocker, serve as a
negative control. (a) ICAM-1 mRNA data are expressed in terms of ratios (ICAM-1:GAPDH) of pixel densities due to the respective PCR
products. The data are plotted as %, relative to that of control incubations. (b) ICAM-1 protein levels are expressed in terms of
absorbance at 450 nm, net that of background. The net absorbances were plotted as % of that due to control incubations. The data,
shown as mean7S.D., were derived from 12 sputum sol samples, each tested in triplicate. Po0.05, Po0.01, Po0.001 when
compared with NHBE cultures that were stimulated with sputum sol but had not been treated with drugs.
S.C.H. Chan et al.296the route of delivery and accessibility of the target at the
tissue/organ level. In reports of the use of triptolide in
rheumatoid arthritis, toxicity is a major limitation in its
clinical application,41 particularly toxicity in the renal and
cardiac systems.42In the present study, we demonstrated upregulation of
ICAM-1 protein expression accompanied by increase in ICAM-1
mRNA, suggesting regulation of gene expression at the
transcriptional level in NHBE cells. This suggestion was
confirmed by observations of lack of increase in basal ICAM-1
ARTICLE IN PRESS
Upregulation of ICAM-1 expression in bronchiectasis 297mRNA expression and protein expression despite exposure to
sputum sol, when actinomycin D and cycloheximide were
included in NHBE cultures, respectively. Signal transduction
pathways involved in the activation of ICAM-1 gene expres-
sion were found to include protein kinase C, MAP kinase and
the nuclear factor NF-Kappa B signaling cascade.24,43 The
promoter region of human ICAM-1 consists of not only the
glucocorticoid response element (GRE) and the interferon-
stimulated response element (ISRE) but also a putative
recognition sequence of NF-Kappa B.44 Among these, the NF-
Kappa B family proteins appear to be essential for enhancing
ICAM-1 gene expression. Deletion of NF-Kappa B promoter
sequences resulted in reduction of the rhinovirus-induced
ICAM-1 expression in A549 type II pulmonary cells.45
Ibuprofen can inhibit the activation and translocation of
NF-Kappa B into the nucleus,46,47 while the molecular
mechanism of dexamethasone in inhibiting gene expression
may be mediated through the interaction between the
activated glucocorticoid receptor and NF-Kappa B.48,49
Moreover, a recent study has shown that triptolide is a
potent inhibitor of the NF-Kappa B signaling pathway.22 It is
thus conceivable that down-regulation of ICAM-1 gene
expression by dexamethasone, ibuprofen, MK-663 or tripto-
lide is mediated through the NF-Kappa B signaling pathway.Conclusion
In summary, the study has provided evidence that bronchial
secretions in bronchiectasis is capable of stimulating ICAM-1
expression in bronchial epithelial cells, and that TNF-a in
the secretions is an important mediator. Apart from anti-TNF
antibody, several pharmacologic agents can mitigate this
upregulation in vitro. The findings provide further insights
into the pathogenetic mechanisms in bronchiectasis and the
potential development of therapies in the management of
this disease.Conflict of interest
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